Sapphiros
PrivateLast Round
Series B
Jan 4, 2024
Total Funding Raised
$41.1M
Company Overview
Sapphiros operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2024.
Sapphiros is a consumer diagnostics company that develops and manufactures point-of-care and at-home diagnostic technologies, including lateral flow tests, molecular detection platforms, and patch-based collection systems.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Sensors, Smart Manufacturing
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sapphiros Comparables
Compare Sapphiros with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aptitude Medical | 82% | |
| Visby Medical | 78% | |
| OraSure Technologies Inc | 77% |
For institutional investors. Book with your work email.
Sapphiros Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 4, 2024 | ||||
| Grant | Apr 17, 2023 | ||||
| Corporate Funding | Jul 21, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sapphiros Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Biomedical Imaging and Bioengineering | Grant |
| Kohlberg Kravis Roberts | Corporate Funding |
| NIH RADx | Grant |
| Neoenta | Corporate Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
Monthly visitors increased 51% MoM, reaching 1.5K.
- Feb 27, 2024
Grew 19% QoQ, from 42 to 50 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- merges_withNov 4, 2026
Sapphiros and binx health, inc. merge into a new company called Onvaro in New York on Nov 4th '26.
For institutional investors. Book with your work email.
Sapphiros Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sapphiros's valuation, stock price, and market status.
Is Sapphiros a public or private company?
Sapphiros is a private company.
What is the current stock price of Sapphiros?
Sapphiros is a private company, so its shares have no public market price. Caplight tracks Sapphiros's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sapphiros worth (valuation)?
Valuation information for Sapphiros is not publicly available.
Can I buy Sapphiros stock?
Sapphiros shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sapphiros's last funding round?
Sapphiros's most recent funding round was Series B on January 4, 2024.
Who are the main investors in Sapphiros?
Key investors in Sapphiros include Kohlberg Kravis Roberts.
Will Sapphiros IPO soon?
No public IPO plans have been announced for Sapphiros.
How can I track Sapphiros secondary market activity?
Caplight tracks bids, offers, and trades in Sapphiros's shares on secondary markets.